Evidence map›Paper›PMID 37400485›Full record

ArticleScientific reports2023

Determining buffer conditions for downstream processing of VLP-based recombinant hepatitis B surface antigen using multimodal resins in bind-elute and flow-through purification modes.

Maryam Moazami Goodarzi, Reza Jalalirad, Delaram Doroud, Hamidreza Hozouri, Mohammadreza Aghasadeghi, Mahdi Paryan

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Maryam Moazami GoodarziDepartment of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Karaj, 3159915111, Iran.
Reza JalaliradDepartment of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Karaj, 3159915111, Iran. r_jalalirad@pasteur.ac.ir.ORCID 0000-0003-1826-2570
Delaram DoroudDepartment of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Karaj, 3159915111, Iran. d_doroud@pasteur.ac.ir.ORCID 0000-0003-4167-9921
Hamidreza HozouriDepartment of Quality Management, Production and Research Complex, Pasteur Institute of Iran, Karaj, 3159915111, Iran.
Mohammadreza AghasadeghiDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, 1316943551, Iran.
Mahdi ParyanDepartment of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Karaj, 3159915111, Iran.
Pasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The difficulties in purification of VLP-based recombinant hepatitis B surface antigen (rHBsAg) are mainly emerged from inefficient semi-purification step plus proteins physicochemical properties and these issues make the downstream processing (DSP) very lengthy and expensive. In this study, optimization of rHBsAg (recombinantly-expressed in Pichia pastoris) DSP was performed using selection of buffering conditions in the semi-purification step. In the semi-purification optimization step, up to 73% of the protein impurities were eliminated and the utmost increase in rHBsAg purity (ca. 3.6-fold) was achieved using 20 mM sodium acetate, pH 4.5. By using rHBsAg binding and nonbinding situations obtained from the response surface plot in design of experiments (DOE), additional bind-elute and flow-through purification mode experiments were conducted and rHBsAg with high purity (near 100%) and recovery (> 83%) was achieved. Following assessment of critical quality attributes (i.e., purity, particle size distribution, host cell DNA, host cell protein, secondary structures, specific activity and relative potency), it was indicated that the characteristics of rHBsAg purified by the new DSP were similar or superior to the ones obtained from conventional DSP. The purification performance of the resin was constantly retained (97-100%) and no significant resin damage took place after 10 adsorption-elution-cleaning cycles. The new DSP developed for production of rHBsAg in this study can substitute the conventional one with granting satisfactory target protein quality, long-lasting resin efficacy, shorter and less expensive process. This process may be also employable for purification of both non-VLP- and VLP- based target proteins expressed in the yeast.

Indexed as

Hepatitis B Surface AntigensPichiaRecombinant ProteinsHepatitis B Surface AntigensRecombinant Proteins

Identifiers

PMID37400485
PMCPMC10318023
OpenAlexW4382937372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.